Edgewise Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Edgewise Therapeutics, Inc. (EWTX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $11.70 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2022-02-24
- Edgewise Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $11.70M, a 160.00% increase from fiscal 2020.
- Edgewise Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $4.50M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2021-12-31 | $11.70M 10-K · filed 2022-02-24 |
| 2020-12-31 | $4.50M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |